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Abstract: The peptidic nature of anti-IAPs N-terminus Smac-derived peptides precludes their utiliza- 
tion as potential therapeutic anticancer agents. Recent advances in the development of novel Smac- 
derived peptidomimetics and non-peptidic molecules with improved anti-IAPs activity and  resistance 
to proteolytic cleavage have been reported and led to a number of candidates that are currently in clini- 
cal trials including LCL-161, SM-406/AT-406, GDC-0512/GDC-0917, and birinapant. As an   attempt 
to improve the proteolytic stability of Smac peptides, we developed the Aza-peptide   AzaAla-Val-Pro- 
Phe-Tyr-NH2 (2). Unlike unmodified peptide Ala-Val-Pro-Phe-Tyr-NH2 (1), analogue (2) exhibited resistance towards 
proteolytic cleavage by two aminopeptidases; LAP and DPP-IV, while retaining its IAP inhibitory activity. This was due 
to the altered planar geometry of the P1 residue side chain. Our findings showed that using aza-isosteres of bioactive pep- 
tide sequences imbue the residue with imperviousness to proteolysis; underscoring a potential approach for developing a 
new generation of Smac-derived Aza-peptidomimetics. 
Keywords: Aminopeptidases, Apoptosis, Aza-peptides, Caspase 9, IAPs, Smac. 
 
INTRODUCTION 
Inhibition of the anti-apoptotic IAPs proteins by short 
peptides derived from the N-terminal sequence of the pro- 
apoptotic mitochondrial protein Smac is an emerging strat- 
egy for re-engaging apoptosis in resistant cancer cells over- 
expressing IAPs. Although Smac-derived peptides have been 
demonstrated to augment the activity of anticancer  drugs 
both in-vitro and in-vivo [1, 2], their entirely peptidic nature 
almost certainly precludes their utilization as anticancer 
therapeutic agents. This is because of the innate and gener- 
ally impaired bioavailability of peptide ligands mainly due to 
their instability towards proteolytic cleavage. There have 
been long standing efforts in developing protease-resistant 
Smac-derived peptidomimetics (monovalent and bivalent) 
and non-peptidic analogues by ourselves [3] and many other 
groups [4-9] that led in some cases to IAP inhibitors that 
reached clinical trials [10] such as LCL-161 [11,12], SM- 
406/AT-406   [13,14],   GDC-0512/GDC-0917   [15,16], and 
birinapant [17,18], and thus are drug-like compounds with 
suitable efficacy, bioavailability and tolerability. 
Consequently, we have been interested in enhancing the 
proteolytic resistance of the N-terminal Smac-derived pen- 
tapeptide analogue Ala-Val-Pro-Phe-Tyr-NH2 (1). With re- 
gards to the N-terminus Smac sequence, many studies have 
shown the crucial role of the P1 Ala residue for its IAP in- 
hibitory  activity. According  to  the reported  NMR structure 
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(PDB: 1G3F) [19], P1 Ala is involved in electrostatic inter- 
action with the proximal Glu314 of XIAP BIR3 through the 
N-terminal amino group (Fig. 1 [3], PDB: 1G3F [19]). Also, 
the Ala ɑ- methyl group snugly fits into the hydrophobic 
pocket formed by W310, interacting with the indole ring of 
the pocket (Fig. 1 [3], PDB: 1G3F [19]). Thus, protecting the 
crucial P1 Ala residue against hydrolysis by aminopeptidases 
has to be achieved without interference with these key inter- 
actions. 
Since the acylation of the amino function of the P1 Ala 
residue of Smac abolished the binding affinity of the Smac 
peptide to XIAP BIR3 [19], as did N,N-dimethylation [4], 
such structural modifications cannot be applied for hindering 
the possible exposure of the N-terminal segment of the pep- 
tide to proteolytic cleavage. It is worth mentioning here that 
only the N-terminally mono-methylated (N-methyl) Smac- 
derived peptides have preserved IAP inhibitory activity [4], 
and the this modification is thus currently widely used as an 
aminopeptidase resistant residue at P1 in the Smac-derived 
peptidomimetic and in non-peptidic clinical candidates [11- 
18]. 
Based on the above discussed SAR, we have investigated 
the replacement of the N-terminal alanine of  peptide (1), 
with aza-alanine (AzaAla) residue. Many studies demon- 
strated that the incorporation of aza-amino acids into suscep- 
tible peptidase cleavage sites in peptides renders them less 
likely to be hydrolysed and thus enhancing the peptide se- 
quence metabolic stability, biological action and elongating 
the  duration  of  action  [21].  We  had  anticipated  that   the 
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Figure 1. Smac/DIABLO-derived N-terminal sequence AVPI 
(orange) in the XIAP BIR3 binding pocket; generated from PDB: 
1G3F [19]. Only residues forming the direct contacts with the pep- 
tide are visualized and the shape of the binding  cavity  is shown 
with the surface-like representation coloured based on the  location 
of the negative and positive charge residues. Reprinted from Bioor- 
ganic and Medicinal Chemistry 2013, 21, Elsawy M. A., Martin L., 
Tikhonova I. G., Walker B., Solid phase synthesis of Smac/ 
DIABLO-derived peptides using a‘Safety-Catch’ resin: Identifica- 
tion of potent XIAP BIR3 antagonists, 5004-5011, Copyright 2013, 
with permission from Elsevier [3]. 
 
modified peptide AzaAla-Val-Pro-Phe-Tyr-NH2 (2)  could 
still make the important electrostatic contacts within the 
XIAP BIR3 binding pocket, by virtue of the retained and 
unmodified primary amino function of the AzaAla residue, 
whilst exhibiting enhanced stability towards aminopeptidases 
(exemplified  mainly by  LAP). All this is due to  the  altered 
geometry at P1, where the side chain residue of the SP2      hy- 
bridised aza-amino acid is considered to adopt a planar con- 
formation when compared to the tetrahedral conformation of 
the natural SP3 hybridised L- amino acid (Fig. 2). This letter 
thus  reports  on  the  synthesis  of  the  Smac-derived    Aza- 
peptide (2), testing its stability towards LAP compared to 
peptide (1), and an examination of its ability to re-engage 
caspase-9 activation for apoptosis in cell lysates obtained 




To a stirred solution of 1-(tert-butoxycarbonyl)-1- 
methylhydrazine (12) (8.1 g, 55.4 mmol) in THF/H2O (70/70 
mL) in a 500 mL two neck round bottom flask was added 
solid sodium bicarbonate (9.3 g, 110.7 mmol) followed by a 
solution of Fmoc-OSu (20.5 g, 60.76 mmol) in THF (140 
ml). The latter was added dropwise using a dropping funnel 
over 30 minutes. The reaction mixture was stirred overnight 
at room temperature, after which the THF was separated and 
the aqueous phase was washed with diethyl ether (3 x 25 
mL). The combined organic extracts were washed with H2O, 
separated, dried over anhydrous magnesium sulphate, fil- 
tered and concentrated under reduced pressure to afford yel- 
low viscous oil (18 g) (4) that was directly used in the next 




TFA (50 mL) was added to the yellow oil (4) obtained 
above- and the reaction mixture was stirred, at room tem- 
perature, overnight. The reaction mixture was then concen- 
trated under vacuum in a well-ventilated fume hood to give 
reddish viscous oil. The residual oil was dissolved in 
H2O/ethyl acetate mixture (50/30 mL), stirred at room tem- 
perature and sodium bicarbonate solid was added till no ef- 
fervescence was observed (pH 9). A white precipitate was 
formed, which was filtered, washed with ethyl acetate and 
dried  under  vacuum  to  afford  12.56  g  (84.6%)  of 2-(9H- 
Fluoren-9-methoxycarbonylamino)-1-methylhydrazine (5) as 
a white powder of melting point 145-150˚C. 1H NMR 
(CDCl3, 400 MHz) 6 7.94-7.32 (m, 8H), 6.24 (br s, 1H), 4.40 
(d, 2H), 4.16 (t, 1H), 2.58 (s, 3H); 13C NMR (CDCl3, 100 
MHz)  6  157.13,  143.73,  141.36,  127.76,  127.07,  124.97, 
120.01, 67.01, 47.24, 39.29; ESI-Mass m/z 291.3 [M + Na]+. 
 
Coupling of 1-chlorocarbonyl-2-(9H-Fluoren-9- 
methoxycarbonylamino)-1-methylhydrazine (6) to Val- 
Pro-Phe-Tyr-Resin (7) (Scheme 1, Route A) 
To a 50 mL round bottom flask, containing a cold solu- 
tion (-10˚C) of triphosgene (0.66 mmol, 196 mg) and 2-(9H- 
Fluoren-9-methoxycarbonylamino)-1-methylhydrazine (5) (2 
mmol, 536 mg) in 15 mL THF, was added drop wise N- 
methylmorpholine (2 mmol, 220 µl in 300 µL THF), under 








H2N N NH 
O 
-10˚C. A white precipitate of N-methylmorpholinium    chlo- 
ride was formed. The reaction mixture was centrifuged at 
2000 x g for 5 minutes and the supernatant was separated 
and  concentrated  under  vacuum.   1-chlorocarbonyl-2-(9H- 
L-Configuration Planar geometry 
 
Figure 2. Configuration of L-Ala and AzaAla residues. 
 
METHODS 
General Protocol for the Microwave Assisted Solid Phase 
Peptide Synthesis (MW-SPPS) 
Peptides were synthesized using MW-SPPS on Rink Am- 
ide MBHA resin (substitution 0.65 mmol/g, 100-200 mesh) 
and were purified by RP-HPLC as previously described [3]. 
Fluoren-9-methoxycarbonylamino)-1-methylhydrazine     (6) 
residue 500 mg (1.5 mmol, 75% yield) was obtained, ESI- 
Mass for sample dissolved in methanol m/z 324.5 [Fmoc- 
NH-N(CH3)-COOCH3]+.The residue was then used for the 
microwave-assisted coupling to H2N-Val-Pro-Phe-Tyr-Resin 
(7) with DIEA as activator base, where 1-chlorocarbonyl-2- 
Fmoc-1-methylhydrazine /DIEA (1/2). The reaction was 
repeated for 7 cycles (coupling completion was monitored by 
Kaiser Test); each coupling cycle was performed for 10 min- 
utes, at 22 Watts, at a temperature of 75 ºC. After coupling 
completion, the peptide was cleaved from the resin and  puri- 
Commented [ME1]: Please insert the following legend for 
figure 1: 
 
Figure 1. Smac/DIABLO-derived N-terminal sequence AVPI (dark 
grey with Ala in black) in the XIAP BIR3 binding pocket (light grey) 
with only the residues directly interacting with the ligand are 
visualized; generated from PDB: 1G3F [19]  
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fied using RP-HPLC (check under general protocols for the 
MW-SPPS) to obtain AzaAla-Val-Pro-Phe-Tyr-NH2 (2) (8% 
yield and 98% purity after semi-preparative RP-HPLC puri- 
fication), ESI-Mass m/z: 618.6 [M+Na]+. 
 
Coupling of 2-(9H-Fluoren-9-methoxycarbonylamino)-1- 
methylhydrazine (5) to Val-Pro-Phe-Tyr-Resin (7) 
(Scheme 1, Routes B and C) 
For 0.25 mM scale microwave-assisted synthesis of 
AzaAla-Val-Pro-Phe-Tyr-NH2 (2),       2-(9H-Fluoren-9- 
methoxycarbonylamino)-1-methylhydrazine  (5)  (1.5  mmol, 
402  mg, 6  equivalent)  and  carbonyldiimidazole (1.5 mmol, 
243 mg, 6 equivalent) or p-nitrophenyl chloroformate (1.5 
mmol, 302 mg, 6 equivalent) were dissolved in  DMF (6 
mL). DIEA was used as activator base, where 2-Fmoc-1- 
methylhydrazine (5) /DIEA/carbonyldiimidazole or p- 
nitrophenyl chloroformate (1/2/1) for one coupling  cycle. 
The coupling reagents were transferred to the microwave 
reaction vessel for coupling (5) to the resin bound peptide 
H2N-Val-Pro-Phe-Tyr-Resin (7). The reaction was repeated 
for 7 cycles (coupling completion was monitored by Kaiser 
Test and ESI-MS); each coupling cycle was performed for 10 
minutes, at 22 Watts, at a temperature of 75 ºC. 
 
Aminopeptidase Susceptibility Assays 
In 1.5 mL microcentrifuge tube, 940 µL of assay buffer 
(DPP-IV assay buffer: 25 mM Tris, 140 mM NaCl and 10 
mM KCl at pH 7.9; LAP assay buffer: 200 mM Tris and 200 
mM NaCl at pH 8.5) and 10 µL of peptide DMSO solution 
(5 mM final concentration) were incubated at 37˚C 
with/without 50 µL of aminopeptidase enzyme (final con- 
centrations of 150 ng/mL for DPP-IV “human recombinant 
enzyme expressed in SF9 cells” and 3.6 mg/mL for micro- 
somal LAP enzyme type IV-S “from porcine kidney micro- 
somes”). The reaction mixture was sampled (100 µL) at cer- 
tain time points (t = zero, 30, 60, 90, 120, 180, 240, 300 and 
360 minutes) and the reaction was quenched for each sample 
by incubation in a water bath at 95˚C followed by immediate 
cooling on ice for 15 min. The samples were injected onto an 
analytical RP-HPLC to check the peptide degrada- 
tion/stability (using the same analytical RP-HPLC protocol 
described under general protocols for the MW-SPPS). 
 
Caspase-9 Activity Fluorimetric Assay 
MDA-MB-231 cell lysate was prepared by solubilising 
cells pellet (~ 5 x 107 cells) in 1 mL ice cold lysis buffer (50 
mM KCl, 5  mM EGTA, 2  mM  MgCl2, 1  mM DTT,   0.2% 
(w/v) CHAPS and 50 mM HEPES; pH 7.4), supplemented 
with a protease inhibitor cocktail (50 µg/mL Antipain.2HCl, 
40 µg/mL Bestatin, 6 µg/mL Chymostatin, 7 µg/mL Pep- 
statin, 50  µg/mL Phosphoramidon, 1  mg/mL Pefabloc   SC, 
0.5 mg/mL EDTA-Na2 and 2 µg/mL Aprotinin), and was 
incubated on ice for 15 min. Cytochrome c (5 μL; 1 mg/mL) 
and dATP (5 mM) in assay buffer (10 mM HEPES, 0.5 mM 
EGTA, 5 mM DTT and 10% (v/v) glycerol; pH 7.4) were 
added to 25 µL cell lysate into  a 1.5  mL microcentrifuge 
tube (25 µL of assay buffer was used instead for blank) 
with/without 1 µL rhXIAP BIR3 (500 nM final concentra- 
tion) and with/without 0.5 µL treatment peptide in DMSO 
(final concentrations of 1 µM), which were then incubated at 
37˚C for 1 h. Each reaction mixture was then diluted with 65 
µL assay buffer; all were transferred to 96-well microtiter 
plate and then 5 µL of Ac-LEHD-AFC substrate (50 µM 
final concentration) were added per well. A FLUOstar 
OPTIMA spectrofluorimeter (BMG LABTECH, Ortenberg, 
Germany) was used at excitation wavelength of 380-400 nm 
and emis- sion wavelength of 470-500 nm to determine the 
caspase-9 activity through the Ac-LEHD-AFC substrate 
cleavage with the release of 7-amino-4-
trifluoromethylcoumarin fluores- cent moiety. The reactions 
were monitored for 1 h. Reactions were carried out in 
triplicates for accuracy. Finally, percent caspase-9 release 
was calculated from the following formula: 
% caspase 9 derepression = 100 X [slope of treatment curve 
fit/slope of maximum activation (dATP + cyt.c) curve fit] 
 
RESULTS AND DISCUSSION 
 
Synthesis of AzaAla-Val-Pro-Phe-Tyr-NH2 (2) 
The Micro Wwave-assisted solid phase synthesis (MW- 
SPPS) of the target peptide included the coupling of 2-(9H- 
Fluoren-9-methoxycarbonylamino)-1-methylhydrazine (5) to 
the tetrapeptide sequence Val-Pro-Phe-Tyr-tethered to the 
resin (7) (Scheme 1), but first the synthesis of (5) was re- 
quired. Compound (5) was synthesized from 1-(tert- 
butoxycarbonyl)-1-methylhydrazine (3), using the previously 
reported synthesis protocol by Busnel et al. [22] and others 
[23-25]. The synthesis comprises two steps, an initial Fmoc- 
protection of the primary amino function of the hydrazine, 
followed by Boc removal of the secondary amine functional- 
ity (Scheme 1). The introduction of the Fmoc-group was 
accomplished using Fmoc-OSu, in the presence of sodium 
bicarbonate, to obtain (4), which was then treated with TFA 
in order to effect the removal of the Boc-group. The final 
product, N-Fmoc-methyhydrazine (5), was obtained in high 
yield (85%, based on the starting amount of 4). 
The synthesis of the target Aza-peptide (2) was achieved 
as shown  in  Route A  (Scheme 1)  through  the activation of 
(5) by treatment with triphosgene in the presence of N- 
methyl morpholine, at -10˚C, in THF. The product, 1-chloro- 
carbonyl-2-(9H-Fluoren-9-methoxycarbonylamino)-1- 
methylhydrazine (6) was obtained in high yield (75% ,based 
on the amount of starting material 5) and was used directly to 
acylate the resin-bound H2N-Val-Pro-Phe-Tyr-sequence (7) 
using microwave-assisted coupling, employing DIEA as 
activator base (Scheme 1, Route A). Samples of resin were 
subjected to the Kaiser Test and ESI-MS, in order to assess 
the extent of coupling (6). It was found that seven repeat 
coupling cycles (10 minutes/cycle, 22 Watts, 75˚C) were 
required for completion of the reaction. 
Boeglin and Lubell have previously shown that coupling 
of various Fmoc-aza-amino acid chlorides (including 6) to 
the N-terminus amino group of resin tethered  peptides is 
only complete after 6 h reaction in DCM with DIEA as acti- 
vator base using conventional SPPS, and in some cases the 
coupling has to be repeated to ensure completion [24]. Em- 
ploying microwave-assisted coupling, we managed to sig- 
nificantly reduce the coupling reaction time to 70 minutes (7 
cycles x 10 minutes/cycle). Unfortunately, even with this 
repetitive coupling protocol, (2) could only be obtained as a 
low purity (~25%) crude product, as estimated by   analytical 
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P-Nitrophenyl chloroformate (ii) DIEA, Microwave, 
22 watts, 75 C, 
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Scheme 1. On resin microwave-assisted coupling of 2-(9H-Fluoren-9-methoxycarbonylamino)-1-methylhydrazine (5) for the synthesis of 
AzaAla-Val-Pro-Phe-Tyr-NH2 (2); triphosgene activation (Route A), p-nitrophenyl chloroformate activation (Route B) and carbonyldiimida- 
zole activation (Route C). 
 
RP-HPLC (data not shown). This could be due to the infea- 
sibility of purifying the highly active and unstable intermedi- 
ate (6), which necessitates using it as a crude product for 
coupling to the resin bound peptide (7). However, the crude 
Aza-peptide (2) was purified successfully, by semi- 
preparative RP-HPLC, to give a final product with a yield of 
only 8%, but of 98% purity (Fig. 3). 
Triphosgene is not compatible for use within a micro- 
wave-assisted synthesizer, due to it being highly reactive and 
with potential for interaction with the amide groups of the 
microwave compatible solvents DMF and NMP.  Therefore 
in attempts to improve the yield and purity of the product 
and to automate the synthesis, additional carbonylating 
agents were tried for coupling N-Fmoc-methylhydrazine   (5) 





Figure 3. Panel (A) is ESI-MS data for purified AzaAla-Val-Pro-Phe-Tyr-NH2 (2) (calcd. m/z: 595, found m/z: 618 [M+Na]+, 100% relative 
abundance) produced by triphosgene-mediated carbonylation of N-Fmoc-methylhydrazine (5). Panel (B) is the analytical RP-HPLC spectrum 
for purified aza-peptide (2) of retention time 35 min (peak identified by ESI-MS). 
 
to the N-terminal amino group of the resin-tethered peptide 
(7), under microwave conditions. We tried both para- 
nitrophenyl chloroformate (Scheme 1, Route B) and carbon- 
yldiimidazole (Scheme 1, Route C) mediated carbonylation 
and coupling using the conditions described in the experi- 
mental section. Disappointingly, we did not obtain any of the 
target peptide, even after 7-repeat coupling cycles in case of 
para-nitrophenyl chloroformate (data not shown) and in- 
complete coupling was observed when carbonyldiimidazole 
was used as activator, as indicated by ESI-MS analysis (Fig. 
4). Similar observations have been reported by Han et al., in 
the attempted incorporation of two aza-amino acids into tar- 
get sequences when using para-nitrophenyl chloroformate 
and carbonyldiimidazole [26]. This could be due to a low 
inherent reactivity of  the respective aryl carbamates and   N- 
carbonyl imidazoles, or the poor accessibility of these de- 
rivatives to the amino functionality of the tethered peptide 
within the resin matrix, as reported by André et al. [27]. Ul- 
timately, the AzaAla-Val-Pro-Phe-Tyr-NH2  (2) synthesis 
was only successful through the triphosgene-mediated car- 
bonylation approach (Scheme 1, route A). 
 
Aminopeptidase Susceptibility 
Compound (2) was then tested for its stability against two 
aminopeptidases; namely LAP and DPP-IV, and in compari- 
son to the wild-type Smac-derived native sequence Ala-Val- 
Pro-Phe-Tyr-NH2 (1) and the N-methyl alanyl analogue N- 
Me-Ala-Val-Pro-Phe-Tyr-NH2 (9). 





Figure 4. ESI-MS trace for crude AzaAla-Val-Pro-Phe-Tyr-NH2 (2) produced by carbonyldiimidazole-mediated carbonylation of N-Fmoc- 





(a) (b) (c) 
 
Figure 5. RP-HPLC profiles of (a), Smac-derived pentapeptide analogue (1) incubated with LAP, for 30 min, at 37˚C (b), AzaAla-analogue 
(2) and (c), N-Me-analogue (9) incubated with LAP, for 6 h, at 37˚C. 
 
LAP is an aminopeptidase that can cleave N-terminal Ala 
residues from peptides [28]. As anticipated, the P1 Ala resi- 
due was completely hydrolysed from the native peptide se- 
quence (1) in 30 minutes, to give the truncated hydrolysis 
product Val-Pro-Phe-Tyr-NH2, as shown by RP-HPLC and 
ESI-MS (Fig. 5 (a)). Strikingly, the  AzaAla-analogue (2) 
was completely resistant to hydrolysis after 6 h of exposure 
to LAP (Fig. 5 (b)), as was the case with the N-methyl alanyl 
protected analogue (9) (Fig. 5 (c)). These results suggest that 
designing Smac-derived analogues with a planar SP2 hybrid- 
ised Aza-alanyl modified N-terminal will improve the prote- 
olytic resistance for those candidates, making them as resis- 
tant as the widely used N-methyl alanyl congeners. 
Interestingly, the Smac-derived pentapeptide analogue 
(1), AzaAla-analogue (2) and N-Me-Ala-analogue (9) proved 
to be resistant to aminopeptidase DPP-IV after 6 h exposure 
to the enzyme, as observed by RP-HPLC and ESI-MS (data 
not shown). Although  DPP-IV  is  an  N-terminal  dipeptidyl 





Figure 6. Caspase-9 activation data for the N-terminal Smac-derived peptide library. 
 
peptidase that can cleave a dipeptide unit in ‘one bite’ from 
longer peptides with Val at the P2 position [29], it might 
have been expected that all the three Smac-derived peptides 
(1), (2) and (9) would have been subject to degradation by 
this peptidase (they all have Val at P2). However, the pres- 
ence of Pro at P3 makes all of the N-terminal Smac-derived 
sequences intrinsically resistant to DPP-IV, since peptides 
with Pro at P3 are known to function as DPP-IV inhibitors 
[30]. 
 
IAP Antagonistic Activity 
Subsequently, the antagonistic activity of AzaAla- 
analogue (2) against XIAP BIR3 was assessed by caspase-9 
activity recovery assay. In this assay, the ability of the Smac- 
derived analogues to reactivate caspase-9 in the presence of 
its inhibitor rhXIAP BIR3 (500 nM) was determined by the 
increase in caspase-9 activity that they induced. 
Remarkably, the Aza-peptide analogue (2) retained the 
ability to antagonise the inhibitory effect of XIAP BIR3 on 
caspase-9 activation as effective as the wild-type (1) and the 
N-Methyl-Ala- sequence (9) (Fig. 6). In essence,  (2) was 
able to restore 36.2 + 4.9% of caspase-9 activity in the pres- 
ence of 500 nM rhXIAP BIR3, at 1 M compared to 43.1 + 
5.2% for the wild sequence (1) and 51.4 + 7.1% for the N- 
Me-Ala-analogue (9), at the same concentration (mean + SD, 
n=3) (Fig. 6). These results demonstrate that the planar  con- 
formation of the SP2 hybridised AzaAla residue did not dra- 
matically miss-locate the side-chain methyl group at P1 per- 
mitting the essential hydrophobic interaction with the  indole 
ring of the W310 residue of XIAP BIR3 (Fig. 1 [3]). Moreo- 
ver, analogue (2) can still form the essential electrostatic 
interaction with the proximal Glu314 of XIAP BIR3, owing 
to the retained and unmodified N-terminal primary amino 
function of the AzaAla residue (Fig. 1 [3]). 
 
CONCLUSION 
In the light of the above results, the modified peptide 
AzaAla-Val-Pro-Phe-Tyr-NH2 (2) was a successful bio- 
isostere for the N-terminal Smac-derived pentapeptide parent 
sequence  Ala-Val-Pro-Phe-Tyr-NH2   (1).  The   Aza-peptide 
(2) is an equipotent analogue for (1) as a XIAP BIR3  inhibi- 
tor, whilst exhibiting enhanced stability towards aminopepti- 
dases, exemplified mainly by LAP, owing to the planar ge- 
ometry of the Aza-Ala residue at P1. Although the reported 
Aza-peptide (2) is not a therapeutic candidate per se, due to 
lack of cell permeability, it represents an important lead 
compound for the development of a new class of anti-cancer 
Smac-derived Aza-peptidomimetic therapeutic candidates. 
Our current studies focus on developing libraries of these 
novel candidates, where the N-terminal Ala residue at P1 is 
occupied with the Aza-Ala isostere instead of  the widely 
used  N-methyl substituted  Ala, with  P2, 3  and  4   residues 
modified as previously reported by ourselves [3] 3 and others 
[4] 4. These  structural modifications of  the  arising  Smac-
derived 
Aza-peptidomimetics are expected to improve the efficacy 
and proteolytic stability of these therapeutic candidates. 
 
LIST OF ABBREVIATIONS 
IAPs = Inhibitor of Apoptosis Proteins 
Smac = Second  mitochondria-derived  activator of 
caspases 
XIAP BIR3  = X-linked  Inhibitor  of  Apoptosis  Protein- 
Baculovirus IAP Repeat-3 domain 
SAR = Structure Activity Relationship 
LAP = Leucine Aminopeptidase 
DPP-IV = Dipeptidyl Peptidase-IV 
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